EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: Review of preliminary findings and risk/benefit assessment

Toxicology Mechanisms and Methods

Volumn 23, Issue 1, 2013, Pages 11-17

  Born, Tammy ^a   Kontoghiorghe, Christina N ^b   Spyrou, Aspasia ^b   Kolnagou, Annita ^b   Kontoghiorghes, George J ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Chelation therapy; Clinical applications; Coronary artery diseases; EDTA chelation; Metal detoxification

Indexed keywords

ALUMINUM; CADMIUM; EDETATE DISODIUM; HEAVY METAL; LEAD; MINERAL; NICKEL; VITAMIN; XENOBIOTIC AGENT;

ADULT; AGED; CARDIAC PATIENT; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DETOXIFICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; LEAD POISONING; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY EXCRETION; URINE LEVEL;

AGED; AGED, 80 AND OVER; CHELATING AGENTS; CHELATION THERAPY; CLINICAL TRIALS AS TOPIC; EDETIC ACID; FEMALE; HUMANS; MALE; METALS, HEAVY; MIDDLE AGED; POISONING; RISK ASSESSMENT;

EID: 84871403236     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2012.730562     Document Type: Review

References (41)

1. Adams JB, Holloway CE, George F, Quig D. 2006. Analyses of toxic metals and essential minerals in the hair of Arizona children with autism and associated conditions, and their mothers. Biol Trace Elem Res 110:193-209. (Pubitemid 44127933)
2. Al-Refaie FN, Wonke B, Wickens DG, Aydinok Y, Fielding A, Hoffbrand AV. 1994. Zinc concentration in patients with iron overload receiving oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. J Clin Pathol 47:657-660.
3. Anderson TJ, Hubacek J, Wyse DG, Knudtson ML. 2003. Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. J Am Coll Cardiol 41:420-425. (Pubitemid 36164496)
4. Anonymous. Royal Society of Chemistry Data Book. Stability constants for metal ion complexes. Available at: www. chemsoc. org/networks/learnnet/data. htm
5. Arkadopoulos N, Nastos C, Kalimeris K, Economou E, Theodoraki K, Kouskouni E, Pafiti A, Kostopanagiotou G, Smyrniotis V. 2010. Iron chelation for amelioration of liver ischemia-reperfusion injury. Hemoglobin 34:265-277.
6. Bamonti F, Fulgenzi A, Novembrino C, Ferrero ME. 2011. Metal chelation therapy in rheumathoid arthritis: A case report. Successful management of rheumathoid arthritis by metal chelation therapy. Biometals 24:1093-1098.
7. Baxter AJ, Krenzelok EP. 2008. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila) 46:1083-1084.
8. Blanusa M, Varnai VM, Piasek M, Kostial K. 2005. Chelators as antidotes of metal toxicity: Therapeutic and experimental aspects. Curr Med Chem 12:2771-2794. (Pubitemid 41601574)
9. Brown MJ, Willis T, Omalu B, Leiker R. 2006. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics 118:e534-e536. (Pubitemid 46085393)
10. Carven PC, Morrelli HF. 1975. Chelation therapy. West J Med 122:277-278.
11. De Bie P, Muller P, Wijmenga C, Klomp LW. 2007. Molecular pathogenesis of Wilson and Menkes disease: Correlation of mutations with molecular defects and disease phenotypes. J Med Genet 44:673-688. (Pubitemid 350161581)
12. Discalzi G, Pira E, Herrero Hernandez E, Valentini C, Turbiglio M, Meliga F. 2000. Occupational Mn parkinsonism: Magnetic resonance imaging and clinical patterns following CaNa2-EDTA chelation. Neurotoxicology 21:863-866.
13. Elihu N, Anandasbapathy S, Frishman WH. 1998. Chelation therapy in cardiovascular disease: Ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane. J Clin Pharmacol 38:101-105. (Pubitemid 28117364)
14. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. 2010. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148:466-475.
15. Foglieni C, Fulgenzi A, Ticozzi P, Pellegatta F, Sciorati C, Belloni D, Ferrero E, Ferrero ME. 2006. Protective effect of EDTA preadministration on renal ischemia. BMC Nephrol 7:5.
16. Gil HW, Kang EJ, Lee KH, Yang JO, Lee EY, Hong SY. 2011. Effect of glutathione on the cadmium chelation of EDTA in a patient with cadmium intoxication. Hum Exp Toxicol 30:79-83.
17. Green DJ, O'Driscoll JG, Maiorana A, Scrimgeour NB, Weerasooriya R, Taylor RR. 1999. Effects of chelation with EDTA and vitamin B therapy on nitric oxide-related endothelial vasodilator function. Clin Exp Pharmacol Physiol 26:853-856. (Pubitemid 29513622)
18. Grier MT, Meyers DG. 1993. So much writing, so little science: A review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 27:1504-1509. (Pubitemid 24005152)
19. Haldane SL, Davis RM. 2009. Acute toxicity in five dogs after ingestion of a commercial snail and slug bait containing iron EDTA. Aust Vet J 87:284-286.
20. Hininger I, Waters R, Osman M, Garrel C, Fernholz K, Roussel AM, Anderson RA. 2005. Acute prooxidant effects of vitamin C in EDTA chelation therapy and long-term antioxidant benefits of therapy. Free Radic Biol Med 38:1565-1570. (Pubitemid 40726063)
21. Hoffbrand AV, Kontoghiorghes GJ. 1992. Protocol for monitoring efficacy and toxicity in clinical trials with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). Drugs Today (Barc. ) 28:149-155. (Pubitemid 23038100)
22. Kolnagou A, Kleanthous M, Kontoghiorghes GJ. 2010. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/ deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol 85:430-438.
23. Kontoghiorghes GJ, Jackson MJ, Lunec J. 1986. In vitro screening of iron chelators using models of free radical damage. Free Radic Res Commun 2:115-124.
24. Kontoghiorghes GJ, Neocleous K, Kolnagou A. 2003. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 26:553-584. (Pubitemid 36724096)
25. Kontoghiorghes GJ. 2005. Regulatory molecules and chelators used for the control of essential and toxic metals in health and disease: From molecular interactions to clinical effects and applications. Curr Med Chem 12:2661-2662.
26. Kontoghiorghes GJ, Kolnagou A. 2005. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: The role of natural and synthetic chelators. Curr Med Chem 12:2695-2709. (Pubitemid 41601568)
27. Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. 2005. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr Med Chem 12:2663-2681. (Pubitemid 41601566)
28. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. 2012. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J 163:7-12.
29. Lewin MR. 1997. Chelation therapy for cardiovascular disease. Review and commentary. Tex Heart Inst J 24:81-89. (Pubitemid 27273123)
30. Lin JL, Lin-Tan DT, Hsu KH, Yu CC. 2003. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 348:277-286.
31. Lin-Tan DT, Lin JL, Yen TH, Chen KH, Huang YL. 2007. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases. Nephrol Dial Transplant 22:2924-2931.
32. Morgan BW, Kori S, Thomas JD. 2002. Adverse effects in 5 patients receiving EDTA at an outpatient chelation clinic. Vet Hum Toxicol 44:274-276.
33. Navas-Acien A, Silbergeld EK, Sharrett R, Calderon-Aranda E, Selvin E, Guallar E. 2005. Metals in urine and peripheral arterial disease. Environ Health Perspect 113:164-169. (Pubitemid 40326325)
34. Pippard MJ, Jackson MJ, Hoffman K, Petrou M, Modell CB. 1986. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol 36:466-472. (Pubitemid 16096161)
35. Rajapurkar MM, Alam MG, Bhattacharya A, Shah S. 2007a. Novel treatment for diabetic nephropathy. J Am Soc Nephrol 18:329A.
36. Rajapurkar MM, Gang S, Dabhi M, Kulkarni PS. 2007b. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol 18:57-58A.
37. Roussel AM, Hininger-Favier I, Waters RS, Osman M, Fernholz K, Anderson RA. 2009. EDTA chelation therapy, without added vitamin C, decreases oxidative DNA damage and lipid peroxidation. Altern Med Rev 14:56-61.
38. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. 2007. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115:1876-1884. (Pubitemid 46598901)
39. Tefler P, Goen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. 2006. Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 91:1187-1192. (Pubitemid 44408428)
40. Owda AK, Alam MG, Shah SV. 2003. Environmental lead exposure and chronic renal disease. N Engl J Med 348:1810-2; author reply 1810. (Pubitemid 36514715)
41. Villarruz MV, Dans A, Tan F. 2002. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev 4:CD002785.